http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
- 中文 을 입력하시려면 zhongwen을 입력하시고 space를누르시면됩니다.
- 北京 을 입력하시려면 beijing을 입력하시고 space를 누르시면 됩니다.
RISS 인기검색어
- 검색키워드
- 저자 : 이성계 ( Sung Kae Lee ) (검색결과 1 건)
- 무료
- 기관 내 무료
- 유료
-
진행성 간세포암에 대한 Epirubicin , Cisplatin 및 5 - FU 병용 화학요법의 치료효과
박병채 ( Byung Chae Park ),한병훈 ( Byung Hoon Han ),이상욱 ( Sang Wook Lee ),구자영 ( Ja Young Koo ),서승연 ( Sung Yeon Suh ),이성계 ( Sung Kae Lee ) 대한소화기학회 1989 대한소화기학회지 Vol.21 No.3
N/A Forty-eight patients with unresectable primary hepatocellular carcinoma (PHC), not complicated with ascites (Group IIA) and 39 patients with ascites (Group IIB) were treated with a combination of Epirubicin (60 mg/m, IV, Day 1, q 3 weeks), cisplatin (60 mg/m, IV, Day 2, q 3 weeks) and 5 -fluorouracil (1000 mg, IV, Day 3, q 3 weeks). Partial response (PR: tumor had diminished at least 50 % from its original size) and survival rate of the treated patients were closely matched and compared with those of the untreated control patients (118 cases) who had similar tumor burden, performance status, and the presence or absence of ascites. This regimen was, in most cases, safe with moderate toxicity: nausea, vomiting, temporary ascites formation, and hair loss. PR in Group IIA was observed in 9 cases, always within the third dose with a 18.7% response rate. No complete response was observed in this group of patients. In Group IIB patients, however, PR was observed in only one case. Thirty-two (77%) of 42 symptomatic Group IIA and 13 (36%) of 36 symptomatic Group IIB patients achieved pain reduction. Survival rate of Group IIA patients (46% at 24 weeks and 20% at 48 weeks) was significantly (p<0.05) higher than those of the untreated control patients (Group IA: 20% at 24 weeks and 0% at 48 weeks). Though survival rate of Group IIB patients (9% at 16 weeks and 4% at 16 weeks) was somewhat better than contrcl patients (Group IB: 4% at 16 weeks and 0% 24 weeks), this figure was not significant statistically. In conclusion, this therapy has given more anticancer effect to the patients with advanced PHC, not complicated with ascites, than the other systemic chemotherapy. And therefore, it can be expected to be useful as a first-choice for PHC patients without ascites, prior to, or unsuitable for, chemoembolization and/or radioembolization therapy.
연관 검색어 추천
이 검색어로 많이 본 자료
활용도 높은 자료
